pentoxifylline has been researched along with Cholestasis in 10 studies
Cholestasis: Impairment of bile flow due to obstruction in small bile ducts (INTRAHEPATIC CHOLESTASIS) or obstruction in large bile ducts (EXTRAHEPATIC CHOLESTASIS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Intrahepatic cholestasis is a common pathological condition of several types of liver disorders." | 5.91 | Quercetin potentiates the hepatoprotective effect of sildenafil and/or pentoxifylline against intrahepatic cholestasis: Role of Nrf2/ARE, TLR4/NF-κB, and NLRP3/IL-1β signaling pathways. ( Ali, FEM; Fathy, M; Fawzy, MA; Nasr, G, 2023) |
| "Intrahepatic cholestasis is a common pathological condition of several types of liver disorders." | 1.91 | Quercetin potentiates the hepatoprotective effect of sildenafil and/or pentoxifylline against intrahepatic cholestasis: Role of Nrf2/ARE, TLR4/NF-κB, and NLRP3/IL-1β signaling pathways. ( Ali, FEM; Fathy, M; Fawzy, MA; Nasr, G, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (50.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fawzy, MA | 1 |
| Nasr, G | 1 |
| Ali, FEM | 1 |
| Fathy, M | 1 |
| Andrade, Wde C | 2 |
| Tannuri, U | 2 |
| da Silva, LF | 1 |
| Alves, VA | 2 |
| Silva, LF | 1 |
| Coelho, MC | 1 |
| Tannuri, AC | 1 |
| Tarçin, O | 2 |
| Avşar, K | 1 |
| Demirtürk, L | 1 |
| Gültepe, M | 1 |
| Oktar, BK | 1 |
| Ozdoğan, OC | 1 |
| Baloğlu, H | 1 |
| Gürbüz, AK | 1 |
| Bemelmans, MH | 1 |
| Gouma, DJ | 1 |
| Greve, JW | 1 |
| Buurman, WA | 1 |
| Sánchez, S | 1 |
| Albornoz, L | 1 |
| Bandi, JC | 1 |
| Gerona, S | 1 |
| Mastai, R | 1 |
| Swain, MG | 1 |
| Appleyard, CB | 1 |
| Wallace, JL | 1 |
| Maric, M | 1 |
| Park, EJ | 1 |
| Ko, G | 1 |
| Kim, J | 1 |
| Sohn, DH | 1 |
| Raetsch, C | 1 |
| Jia, JD | 1 |
| Boigk, G | 1 |
| Bauer, M | 1 |
| Hahn, EG | 1 |
| Riecken, EO | 1 |
| Schuppan, D | 1 |
| Gal'perin, EI | 1 |
| Tatishvili, GG | 1 |
| Akhaladze, GG | 1 |
| Sakevarashvili, GR | 1 |
| Nasirov, FN | 1 |
| Aref'ev, AE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Trial of Pentoxifylline in Newly-Diagnosed Biliary Atresia[NCT01774487] | Phase 2 | 17 participants (Actual) | Interventional | 2013-02-04 | Terminated (stopped due to Target enrollment was not reached because the medication, pentoxifylline, has a taste that is not well tolerated by infants. The study team decided to end the study before meeting the enrollment goal because of the medication taste.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The investigators will record the ALT levels at age two years, in patients who had previously been treated with PTX therapy and still have their native liver. Scale 14-45 U/L, with a higher level indicating a worse outcome. (NCT01774487)
Timeframe: 2 years of age
| Intervention | U/L (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 160 |
The investigators will track the weight of patients over the course of therapy in patients receiving 90 days of PTX (this is recorded as part of routine clinical care). The weight will then be compared to standards to calculate a z-score. Normal weight Z-score is greater than or equal to 0, with a higher number of patients meeting this indicating a better outcome. (NCT01774487)
Timeframe: 12 weeks after starting therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| Pentoxifylline - Group 1 | 0 |
| Group 2 | 0 |
The investigators will track the serum conjugated bilirubin (CB) levels over the course of therapy in patients receiving 90 days of PTX (this laboratory test is drawn as part of routine care). Normal CB is 0.0-0.3 mg/dL, with a higher number of patients meeting this indicating a better outcome. (NCT01774487)
Timeframe: 12 weeks after starting therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| Pentoxifylline - Group 1 | 6 |
| Pentoxifylline - Group 2 | 0 |
The investigators will record platelet levels at age two years, in patients who had previously been treated with PTX therapy and still have their native liver. Scale 189-403*10^3 Platelets/μL, with a lower level indicating a worse outcome. (NCT01774487)
Timeframe: 2 years of age
| Intervention | 10^3 Platelets/μL (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 208 |
"The investigators will measure spleen size by ultrasound at 2 years of age, in patients who had received PTX therapy earlier and still have their native liver. Normal spleen size range (10th-90th percentile) at this age is 6.4-8.6 cm, with a value exceeding this range indicating a worse outcome." (NCT01774487)
Timeframe: 2 years of age
| Intervention | cm (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 10.0 |
The investigators will track time to liver transplant. The shorter time to liver transplant indicates a worse outcome. (NCT01774487)
Timeframe: Baseline and up to two years after therapy finishes
| Intervention | days (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 317 |
| Pentoxifylline - Group 2 | 273 |
10 other studies available for pentoxifylline and Cholestasis
| Article | Year |
|---|---|
Quercetin potentiates the hepatoprotective effect of sildenafil and/or pentoxifylline against intrahepatic cholestasis: Role of Nrf2/ARE, TLR4/NF-κB, and NLRP3/IL-1β signaling pathways.
Topics: Cholestasis; Cholestasis, Intrahepatic; Interleukin-1beta; Liver; NF-E2-Related Factor 2; NF-kappa B | 2023 |
Effects of the administration of pentoxifylline and prednisolone on the evolution of portal fibrogenesis secondary to biliary obstruction-an experimental study in growing animals.
Topics: Animals; Biliary Atresia; Biliary Tract Diseases; Cholestasis; Common Bile Duct Diseases; Disease Mo | 2009 |
Effects of the administration of pentoxifylline and prednisolone on the evolution of portal fibrogenesis secondary to biliary obstruction in growing animals: immunohistochemical analysis of the expression of TGF-β and VEGF.
Topics: Animals; Cholestasis; Disease Models, Animal; Glucocorticoids; Immunohistochemistry; Liver; Liver Ci | 2012 |
In vivo inefficiency of pentoxifylline and interferon-alpha on hepatic fibrosis in biliary-obstructed rats: assessment by tissue collagen content and prolidase activity.
Topics: Animals; Cholestasis; Collagen; Dipeptidases; Disease Models, Animal; Drug Therapy, Combination; Fem | 2003 |
Effect of antitumour necrosis factor treatment on circulating tumour necrosis factor levels and mortality after surgery in jaundiced mice.
Topics: Animals; Antibodies, Monoclonal; Bile Ducts; Cholestasis; Female; Kidney; Lactulose; Mice; Pentoxify | 1993 |
Pentoxifylline, a drug with rheological effects, decreases portal pressure in an experimental model of cirrhosis.
Topics: Animals; Blood Viscosity; Cardiac Output; Cholestasis; Disease Models, Animal; Double-Blind Method; | 1997 |
TNF-alpha facilitates inflammation-induced glucocorticoid secretion in rats with biliary obstruction.
Topics: Adrenocorticotropic Hormone; Animals; Cholestasis; Corticosterone; Glucocorticoids; Hypothalamo-Hypo | 1997 |
Antifibrotic effects of a polysaccharide extracted from Ganoderma lucidum, glycyrrhizin, and pentoxifylline in rats with cirrhosis induced by biliary obstruction.
Topics: Animals; Basidiomycota; Body Weight; Cholestasis; Common Bile Duct Diseases; Female; Glycyrrhetinic | 1997 |
Pentoxifylline downregulates profibrogenic cytokines and procollagen I expression in rat secondary biliary fibrosis.
Topics: Administration, Oral; Animals; Cholestasis; Chronic Disease; Collagen; Cytokines; DNA Probes; DNA, C | 2002 |
[Disorders of organic hemodynamics of the liver and their correction in suppurative cholangitis].
Topics: Acute Disease; Animals; Aprotinin; Ascorbic Acid; Aspirin; Cholangitis; Cholestasis; Dextrans; Dipyr | 1991 |